News

April 4, 2017

Lilly and Ohio University Heritage College of Osteopathic Medicine Partner on Rotation Program for Medical Students
INDIANAPOLIS, April 4, 2017 /PRNewswire/ -- Students from Ohio University's Heritage College of Osteopathic Medicine will soon join Eli Lilly and Company's (NYSE: LLY) innovative rotation program for aspiring physicians. Launched in early 2014, the program provides students with hands-on experience in a range of pharmaceutical business activities, ...

March 24, 2017

Lilly Announces $850 Million Investment in U.S. Capital Projects in 2017
INDIANAPOLIS, March 24, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced plans to invest $850 million in its U.S. operations in 2017. The company's investments span facilities across its U.S. enterprise, including research laboratories, manufacturing sites, and general and administrative areas. The investments are being driven...

March 2, 2017

Lilly Announces Changes in Senior Management
INDIANAPOLIS, March 2, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced changes in its executive committee. Johna Norton will be promoted to senior vice president of global quality April 1, replacing Fionnuala Walsh, who is retiring April 15 after 28 years at Lilly. Norton currently is vice president, Global Qualit...

March 1, 2017

Lilly Completes Acquisition of CoLucid Pharmaceuticals
INDIANAPOLIS, March 1, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of CoLucid Pharmaceuticals, Inc. (NASD:CLCD). The tender offer for all outstanding shares of common stock of CoLucid, at a price of $46.50 per share, expired as scheduled on Tuesday, February 28, 2017. As...

February 9, 2017

Carolyn R. Bertozzi, Ph.D., Elected to Lilly Board of Directors
INDIANAPOLIS, Feb. 9, 2017 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has elected Carolyn R. Bertozzi, Ph.D., as a new member, effective Feb. 10, 2017. As a member of Lilly's board, she will serve on the Science and Technology and Public Policy and Compliance Committees of the board. Professor Bertozzi is the...

February 2, 2017

Japan IP High Court Rules In Lilly's Favor On Alimta Vitamin Regimen Patents
INDIANAPOLIS, Feb. 2, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the Japan IP High Court confirmed the decisions of the Japan Patent Office and ruled in Lilly's favor in the invalidation trials initiated by Sawai regarding Lilly's vitamin regimen patents for Alimta. In the fourth quarter of 2015, the Japan P...

January 18, 2017

Lilly and CoLucid Pharmaceuticals Announce Agreement for Lilly To Acquire CoLucid
INDIANAPOLIS and CAMBRIDGE, Mass., Jan. 18, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and CoLucid Pharmaceuticals, Inc. (NASD: CLCD) today announced an agreement for Lilly to acquire CoLucid for $46.50 per share or approximately $960 million. This all-cash transaction will enhance Lilly's existing portfolio in pain management for migra...

January 12, 2017

U.S. Court of Appeals Rules In Lilly's Favor On Alimta Vitamin Regimen Patent
INDIANAPOLIS, Jan. 12, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Court of Appeals for the Federal Circuit has upheld the district court's decision and ruled in the company's favor regarding validity and infringement of the vitamin regimen patent for Alimta® (pemetrexed for injection). In the ca...

January 5, 2017

Lilly to Adjust Organization and Leadership Structure to Better Align with Growth Opportunities
INDIANAPOLIS, Jan. 5, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a series of changes to its organization and leadership structure to better align them with the company's growth opportunities. Explaining the need for these changes, David A. Ricks, Lilly's president and CEO, said, "Lilly begins 2017 with a clear vie...

January 3, 2017

Elanco Animal Health Completes Acquisition of Boehringer Ingelheim Vetmedica's U.S. Feline, Canine and Rabies Vaccines Portfolio
GREENFIELD, Ind., Jan. 3, 2017 /PRNewswire/ -- Today Elanco US Inc., a subsidiary of Eli Lilly and Company (NYSE: LLY), announced that it has completed the acquisition of Boehringer Ingelheim Vetmedica, Inc's (BIVI) U.S. feline, canine and rabies vaccines portfolio - as well as a fully integrated manufacturing and R&D site and several pipeline asse...

December 9, 2016

Lilly and AstraZeneca to Develop Second Potentially Disease-Modifying Treatment for Alzheimer's Disease
INDIANAPOLIS, Dec. 9, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and AstraZeneca announced a worldwide agreement to co-develop MEDI1814, an antibody selective for amyloid-beta 42 (Aβ42), which is currently in Phase 1 trials as a potential disease-modifying treatment for Alzheimer's disease (AD). This agreement builds on the existin...

November 30, 2016

Lilly Introduces Scholars Programs for Florida A&M University's and Howard University's Business Students
INDIANAPOLIS, Nov. 30, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will deepen its partnership with Florida Agricultural and Mechanical University (FAMU) and Howard University with the inaugural Sybil C. Mobley Scholars Program and the inaugural H. Naylor Fitzhugh Scholars Program. The programs, in part, aim to increase the representation...

Showing 1-12 of 12 Page: 1